Purple Biotech Ltd. (PPBT) Financials

PPBT

FY2025 annual

Revenue Not reported for FY2025

Net Income -$26.5M -264.0% YoY

Free Cash Flow -$5.7M YoY not available

Operating Cash Flow -$5.7M +60.6% YoY

Market Cap $1.9M as of Oct 17, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.2x on $9.7M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 19, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PPBT SEC filings page.

This page shows Purple Biotech Ltd. (PPBT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PPBT FY2025 2026-10-04

Purple Biotech’s shrinking asset base shows recurring operating cash needs and increasing dependence on external equity financing.

Across the latest three valid annual periods, operating cash outflow narrowed from $19.9M to $5.7M. Yet assets fell from $44.3M to $17.6M, suggesting the smaller cash requirement reflects a reduced financial base rather than internally funded expansion.

In FY2025, the net loss was $26.5M while operating cash flow was negative $5.7M, creating a wide cash-conversion gap. Noncash charges or working-capital timing materially affected reported earnings, so the loss does not map directly to cash spending.

Shares outstanding expanded from 178.0M in FY2021 to 1.9B in FY2025, consistent with substantial reliance on external capital. By FY2025, the current ratio was 1.3x and debt-to-equity was 0.8x, indicating a much thinner balance-sheet cushion than earlier periods.

Financial Health Signals

Financial health score not available

Purple Biotech Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Purple Biotech Ltd. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Purple Biotech Ltd. reported a net loss of $26.5M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$8.7M

YoY+17.8%

QoQ+17.8%

Purple Biotech Ltd. held $8.7M in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

1.86B

Purple Biotech Ltd. had 1.86B shares outstanding in Q4 2025.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

PPBT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PPBT quarterly income statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	N/A	N/A	N/A	N/A	N/A	$1.0M0.0%	$1.0M0.0%	$1.0M+900.0%	$100K	N/A	N/A
Interest Expense	$982K+103.3%	$483K-78.0%	$2.2M+3176.1%	$67K+131.6%	-$212K-447.5%	$61K-66.3%	$181K-68.6%	$576K+2115.4%	$26K-57.4%	$61K-73.1%	$227K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	$216K	N/A	N/A	N/A	N/A
Net Income	-$26.5M-264.0%	-$7.3M+63.6%	-$20.0M+8.2%	-$21.8M-217.8%	$18.5M-34.2%	$28.1M+376.4%	$5.9M+5.8%	$5.6M-56.9%	$12.9M+6.5%	$12.1M+188.6%	$4.2M
EPS (Basic)	N/A	N/A	$0.90-25.0%	$1.20+18.8%	$1.01	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	$0.90-25.0%	$1.20+18.8%	$1.01	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	480,053	2M	1M+22.4%	904,054	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2520-F	Q4'2420-F	Q4'2310-K	Q4'2210-K	Q4'2110-K	Q4'2010-K	Q4'1910-K	Q2'1910-Q

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

PPBT Balance Sheet

PPBT quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$17.6M-52.6%	$37.0M-16.4%	$44.3M-18.9%	$54.6M-22.2%	$70.2M-16.2%	$83.8M+469.4%	$14.7M0.0%	$14.7M+3.8%	$14.2M-4.9%	$14.9M	N/A
Current Assets	$9.9M+10.8%	$8.9M-43.6%	$15.8M-52.5%	$33.3M-31.4%	$48.5M-18.2%	$59.3M+614.1%	$8.3M-2.5%	$8.5M+6.7%	$8.0M-46.4%	$14.9M	N/A
Cash & Equivalents	$8.7M+17.8%	$7.4M-48.9%	$14.5M-3.6%	$15.0M+38.0%	$10.9M-3.2%	$11.2M+156.5%	$4.4M-15.1%	$5.2M+30.8%	$3.9M-41.6%	$6.8M-36.0%	$10.6M
Goodwill	N/A	N/A	N/A	$20.7M+1.0%	$20.5M0.0%	$20.5M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.9M+91.7%	$4.1M-58.8%	$10.0M+33.0%	$7.5M+47.8%	$5.1M+25.7%	$4.1M+5.0%	$3.9M+3.8%	$3.7M-32.3%	$5.5M+259.4%	$1.5M	N/A
Current Liabilities	$7.8M+94.5%	$4.0M-58.9%	$9.7M+37.4%	$7.1M+66.1%	$4.3M+37.2%	$3.1M-12.6%	$3.5M+7.0%	$3.3M-16.6%	$4.0M+212.1%	$1.3M	N/A
Non-Current Liabilities	$160K+14.3%	$140K-53.9%	$304K-34.8%	$466K-44.7%	$842K-11.6%	$953K+204.5%	$313K-22.7%	$405K-73.4%	$1.5M+494.5%	$256K	N/A
Long-Term Debt	N/A	N/A	$163K-49.2%	$321K-41.6%	$550K-20.1%	$688K+2357.1%	$28K	N/A	N/A	N/A	N/A
Total Equity	$9.7M-70.7%	$32.9M-4.0%	$34.3M-27.2%	$47.1M-27.7%	$65.1M-18.4%	$79.8M+634.4%	$10.9M-1.3%	$11.0M+26.7%	$8.7M-35.1%	$13.4M+42.0%	$9.4M
Retained Earnings	-$171.1M-18.2%	-$144.7M-5.3%	-$137.5M-16.9%	-$117.6M-22.6%	-$95.9M-23.7%	-$77.5M-56.5%	-$49.5M-13.4%	-$43.7M-13.5%	-$38.5M-46.8%	-$26.2M	N/A

Metric	Q4'2520-F	Q4'2420-F	Q4'2310-K	Q4'2210-K	Q4'2110-K	Q4'2010-K	Q4'1910-K	Q2'1910-Q
Total Assets	$17.6M-52.6%	$37.0M-16.4%	$44.3M-18.9%	$54.6M-22.2%	$70.2M-16.2%	$83.8M+469.4%	$14.7M0.0%	$17.2M-6.4%
Current Assets	$9.9M+10.8%	$8.9M-43.6%	$15.8M-52.5%	$33.3M-31.4%	$48.5M-18.2%	$59.3M+614.1%	$8.3M-2.5%	$10.7M-12.4%
Cash & Equivalents	$8.7M+17.8%	$7.4M-48.9%	$14.5M-3.6%	$15.0M+38.0%	$10.9M-3.2%	$11.2M+156.5%	$4.4M-15.1%	$2.8M-48.6%
Goodwill	N/A	N/A	N/A	$20.7M+1.0%	$20.5M0.0%	$20.5M	N/A	N/A
Total Liabilities	$7.9M+91.7%	$4.1M-58.8%	$10.0M+33.0%	$7.5M+47.8%	$5.1M+25.7%	$4.1M+5.0%	$3.9M+3.8%	$5.8M-25.4%
Current Liabilities	$7.8M+94.5%	$4.0M-58.9%	$9.7M+37.4%	$7.1M+66.1%	$4.3M+37.2%	$3.1M-12.6%	$3.5M+7.0%	$5.4M-25.9%
Non-Current Liabilities	$160K+14.3%	$140K-53.9%	$304K-34.8%	$466K-44.7%	$842K-11.6%	$953K+204.5%	$313K-22.7%	$388K-17.4%
Long-Term Debt	N/A	N/A	$163K-49.2%	$321K-41.6%	$550K-20.1%	$688K+2357.1%	$28K	N/A
Total Equity	$9.7M-70.7%	$32.9M-4.0%	$34.3M-27.2%	$47.1M-27.7%	$65.1M-18.4%	$79.8M+634.4%	$10.9M-1.3%	$11.4M+7.3%
Retained Earnings	-$171.1M-18.2%	-$144.7M-5.3%	-$137.5M-16.9%	-$117.6M-22.6%	-$95.9M-23.7%	-$77.5M-56.5%	-$49.5M-13.4%	-$46.2M-6.7%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments.

PPBT Cash Flow Statement

PPBT quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$5.7M+60.6%	-$14.4M+27.9%	-$19.9M-19.1%	-$16.7M-4374.6%	-$374K-121.9%	$1.7M+186.6%	-$2.0M+76.8%	-$8.5M+1.7%	-$8.6M-37.8%	-$6.3M-89.3%	-$3.3M
Capital Expenditures	$3K	N/A	$3K-88.5%	$26K-77.4%	$115K-26.3%	$156K+1318.2%	$11K-31.3%	$16K+23.1%	$13K+30.0%	$10K+11.1%	$9K
Free Cash Flow	-$5.7M	N/A	-$19.9M-18.9%	-$16.8M-3327.6%	-$489K-131.6%	$1.5M+178.3%	-$2.0M+76.7%	-$8.5M+1.7%	-$8.6M-37.8%	-$6.3M-89.1%	-$3.3M
Investing Cash Flow	$632K+24.2%	$509K-96.3%	$13.9M-30.3%	$19.9M+48.5%	$13.4M+127.0%	-$49.6M-10945.7%	-$449K-122.0%	$2.0M-26.3%	$2.8M+135.7%	-$7.8M-86244.4%	-$9K
Financing Cash Flow	$6.3M-6.5%	$6.8M+24.3%	$5.4M+389.1%	$1.1M	N/A	$68.5M+1208.8%	$5.2M-32.8%	$7.8M+160.0%	$3.0M-70.9%	$10.3M-18.6%	$12.6M

Metric	Q4'2520-F	Q4'2420-F	Q4'2310-K	Q4'2210-K	Q4'2110-K	Q4'2010-K	Q4'1910-K	Q2'1910-Q

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

PPBT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PPBT quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Net Margin	N/A	N/A	N/A	N/A	N/A	2807.4%	589.3%	556.9%	12913.0%	N/A	N/A
Return on Equity	-274.3%-252.2pp	-22.1%+36.1pp	-58.3%-12.0pp	-46.2%-74.6pp	28.4%-6.8pp	35.2%-19.1pp	54.3%+3.7pp	50.6%-98.0pp	148.6%+58.0pp	90.6%+46.0pp	44.6%
Return on Assets	-150.8%-131.1pp	-19.7%+25.4pp	-45.1%-5.3pp	-39.8%-66.1pp	26.3%-7.2pp	33.5%-6.5pp	40.0%+2.2pp	37.8%-53.2pp	91.0%+9.8pp	81.3%	N/A
Current Ratio	1.27-1.0x	2.23+0.6x	1.63-3.1x	4.71-6.7x	11.41-7.7x	19.14+16.8x	2.34-0.2x	2.57+0.6x	2.01-9.7x	11.70	N/A
Debt-to-Equity	0.82+0.7x	0.13+0.1x	0.000.0x	0.010.0x	0.010.0x	0.010.0x	0.00-0.3x	0.34-0.3x	0.63+0.5x	0.11	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.01-0.1x	0.070.0x	0.07+0.1x	0.01	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	154.9%	-197.9%	-849.6%	-8640.0%	N/A	N/A

Metric	Q4'2520-F	Q4'2420-F	Q4'2310-K	Q4'2210-K	Q4'2110-K	Q4'2010-K	Q4'1910-K	Q2'1910-Q
Current Ratio	1.27-1.0x	2.23+0.6x	1.63-3.1x	4.71-6.7x	11.41-7.7x	19.14+16.8x	2.34-0.2x	1.99+0.3x
Debt-to-Equity	0.82+0.7x	0.13+0.1x	0.000.0x	0.010.0x	0.010.0x	0.010.0x	0.00-0.3x	0.50-0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Purple Biotech Ltd. PPBT	FY2025	N/A	-$26.5M	N/A	$1.9M	—
WINDTREE THERAPEUTICS NEW WINT	FY2024	N/A	-$1.8M	N/A	N/A	—
CDT Equity Inc. CDT	FY2025	N/A	N/A	N/A	$181K	—
GT Biopharma Inc. GTBP	FY2025	N/A	-$28.4M	N/A	$12.7M	—
Scinai Immunotherapeutics Ltd. SCNI	FY2025	$1.3M	-$8.3M	N/A	$1.0M	45/100
Psyence Biomedical Ltd. PBM	FY2026	N/A	-$6.9M	N/A	$16.1M	—

Where Purple Biotech Ltd. Ranks

Frequently Asked Questions

Is Purple Biotech Ltd. profitable?

No, Purple Biotech Ltd. (PPBT) reported a net income of -$26.5M in fiscal year 2025.

What is Purple Biotech Ltd.'s return on equity (ROE)?

Purple Biotech Ltd. (PPBT) has a return on equity of -274.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Purple Biotech Ltd.'s free cash flow?

Purple Biotech Ltd. (PPBT) recorded an outflow of $5.7M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Purple Biotech Ltd.'s operating cash flow?

Purple Biotech Ltd. (PPBT) recorded an outflow of $5.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Purple Biotech Ltd.'s total assets?

Purple Biotech Ltd. (PPBT) had $17.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Purple Biotech Ltd.'s capital expenditures?

Purple Biotech Ltd. (PPBT) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Purple Biotech Ltd. have outstanding?

Purple Biotech Ltd. (PPBT) had 1.86B shares outstanding as of fiscal year 2025.

What is Purple Biotech Ltd.'s current ratio?

Purple Biotech Ltd. (PPBT) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.

What is Purple Biotech Ltd.'s debt-to-equity ratio?

Purple Biotech Ltd. (PPBT) had a debt-to-equity ratio of 0.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Purple Biotech Ltd.'s return on assets (ROA)?

Purple Biotech Ltd. (PPBT) had a return on assets of -150.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Purple Biotech Ltd.'s P/E ratio?

Purple Biotech Ltd. (PPBT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.9M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Purple Biotech Ltd.'s price-to-sales ratio?

Purple Biotech Ltd. (PPBT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.9M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Purple Biotech Ltd.'s Piotroski F-Score?

Purple Biotech Ltd. (PPBT) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Purple Biotech Ltd.'s earnings high quality?

Purple Biotech Ltd. (PPBT) reported a net loss of $26.5M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.